The FDA will review an application from Novartis unit Sandoz for rituximab, a biosimilar version of Roche's Rituxan for hematological cancers, rheumatoid arthritis and other immunological diseases, according to a Novartis announcement.
FDA accepts Sandoz's application for biosimilar rituximab
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.